|
|
Article: Hollis-Eden Pharmaceuticals Provides Update on Bone Marrow Regeneration Program and Chemotherapy Indication.
- Article from:
- Business Wire
- Article date:
- October 2, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today an update on its progress in developing novel small molecule compounds with cellular and tissue regenerative properties that could play a beneficial therapeutic role in radiation- and chemotherapy-induced bone marrow suppression. As reported at the 35th Annual Scientific Meeting of the International Society for Experimental Hematology ("ISEH") held September 27-30, 2006, in Minneapolis, Minnesota, and in the November 2006 issue of International Immunopharmacology (available at www.elsevier.com), Hollis-Eden is advancing development of first- and second-generation compounds that demonstrate the ...